Positive Phase III data on the prostate cancer drug Xtandi (enzalutamide) in an expanded indication will take some of the edge off at Pfizer Inc., where the brand's near-term growth prospects fizzled right after the expensive acquisition of Medivation Inc.
Pfizer and Xtandi marketing partner Astellas Pharma Inc. announced positive top-line data from PROSPER Sept. 14. The results showed...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)